LOX AND LOXL2 INHIBITORS AND USES THEREOF
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
1 - 65 . (canceled)
66 . An isolated antibody or antigen binding fragment thereof, comprising a heavy chain variable region having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 25, 26, 27 or 28.
67 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the heavy chain variable region comprises at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 27.
68 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the heavy chain variable region comprises at least 95% identity to the amino acid sequence set forth as SEQ ID NO: 25, 26, 27 or 28.
69 . The isolated antibody or antigen binding fragment thereof of claim 68 , wherein the heavy chain variable region comprises at least 99% identity to the amino acid sequence set forth as SEQ ID NO: 25, 26, 27 or 28.
70 . The isolated antibody or antigen binding fragment of claim 66 , further comprising a light chain variable region having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32.
71 . The isolated antibody or antigen binding fragment of claim 70 , wherein the light chain variable region has at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 32.
72 . The isolated antibody or antigen binding fragment of claim 70 , wherein the light chain variable region has at least 95% identity to the amino acid sequence set forth as 30, 31, or 32.
73 . The isolated antibody or antigen binding fragment of claim 72 , wherein the light chain variable region has at least 99% identity to the amino acid sequence set forth as 30, 31, or 32.
74 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent, or both.
75 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the antibody or fragment is labeled with a therapeutic agent.
76 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab′) 2 , or monoclonal.
77 . The isolated antibody or antigen binding fragment thereof of claim 66 , wherein the antibody or fragment is humanized.
78 . An isolated antibody or antigen binding fragment thereof, comprising:
a heavy chain variable region having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 25, 25, 26, 27 or 28; and
a light chain variable region having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32,
wherein the isolated antibody or antigen binding fragment thereof specifically binds to a LOXL2 protein.
79 . The isolated antibody or antigen binding fragment of claim 78 , wherein the heavy chain variable region has at least 95% identity to the amino acid sequence set forth as SEQ ID NO: 25, 25, 26, 27 or 28 and the light chain variable region has at least 95% identity to the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32.
80 . The isolated antibody or antigen binding fragment of claim 79 , wherein the heavy chain variable region has at least 99% identity to the amino acid sequence set forth as SEQ ID NO: 25, 25, 26, 27 or 28 and the light chain variable region has at least 99% identity to the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32.
81 . The isolated antibody or antigen binding fragment thereof of claim 78 , wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent, or both.
82 . The isolated antibody or antigen binding fragment thereof of claim 78 , wherein the antibody or fragment is labeled with a therapeutic agent.
83 . The isolated antibody or antigen binding fragment thereof of claim 78 , wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab′) 2 , or monoclonal.
84 . The isolated antibody or antigen binding fragment thereof of claim 78 , wherein the antibody or fragment is humanized.
85 . An isolated antibody or antigen binding fragment thereof, comprising:
a variable heavy chain having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 27; and
a variable light chain having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 32,
wherein the isolated antibody or antigen binding fragment thereof specifically binds to a LOXL2 protein.
86 . The isolated antibody or antigen binding fragment thereof of claim 79 , wherein the heavy chain variable region comprises at least 95% identity to the amino acid sequence set forth as SEQ ID NO:27 and the light chain variable region comprises at least 95% identity to the amino acid sequence set forth as SEQ ID NO:31.
87 . The isolated antibody or antigen binding fragment thereof of claim 86 , wherein the heavy chain variable region comprises at least 99% identity to the amino acid sequence set forth as SEQ ID NO:27 and the light chain variable region comprises at least 99% identity to the amino acid sequence set forth as SEQ ID NO:31.
88 . The isolated antibody or antigen binding fragment thereof of claim 85 , wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent, or both.
89 . The isolated antibody or antigen binding fragment thereof of claim 85 , wherein the antibody or fragment is labeled with a therapeutic agent.
90 . The isolated antibody or antigen binding fragment thereof of claim 85 , wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab′) 2 , or monoclonal.
91 . The isolated antibody or antigen binding fragment thereof of claim 85 , wherein the antibody or fragment is humanized.
92 . A pharmaceutical composition comprising an isolated antibody or antigen binding fragment thereof and a pharmaceutical acceptable carrier, wherein the isolated antibody or antigen binding fragment thereof comprising:
a variable heavy chain having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 25, 25, 26, 27 or 28; and a variable light chain having at least 90% identity to the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32.
93 . The pharmaceutical composition of claim 92 , wherein composition may be administered intravenously, intraarterially, intramuscularly, subcutaneously, orally, or topically.